Farm animals and aquaculture cryopreservation partnership announced
With the aim to jointly commercialise a global cryopreservation offering for farm animals and aquaculture, Vitrafy Life Sciences Limited has announced that it has entered a 12-month Strategic Commercial Agreement with IMV Technologies — a French-based multinational conglomerate with over 500 million animal inseminations annually.
In a statement about the agreement, Vitrafy said the partnership is designed to integrate its next-generation cryopreservation technology with IMV’s globally recognised offering. “This agreement with IMV Technologies represents a significant step in Vitrafy’s commercialisation strategy,” Managing Director and CEO Brent Owens said.
“By partnering with the global leader in animal reproduction, we accelerate the validation and adoption of our cryopreservation technology at scale,” Owens added. “This Agreement creates immediate revenue opportunities but also positions Vitrafy for long-term growth through global market access, while we continue to advance our human health strategy in North America.”
Oliver Kohlhaas, CEO of IMV Technologies, commented: “Vitrafy’s unique nitrogen-free cryopreservation technology has the potential to improve post-thaw cell viability. We are excited to collaborate with Vitrafy to offer even better solutions for our customers.”
CTA granted for CAR-T cell therapy for multiple myeloma
The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...
2026 Snow Fellowship recipients to receive $24m in biomedical funding
Australian biomedical researchers Dr Deborah Burnett, A/Prof Sudarshini Ramanathan and Dr Ira...
$780m Sydney Biomedical Accelerator gains its founding Executive Director
Professor Victoria Cogger has been appointed as founding Executive Director of the Sydney...
